Gina Mauro

Gina Mauro

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing OncLive®, Oncology Nursing News®, and Medical World News®. Gina joined the company in 2015 and has held various positions on OncLive and Oncology Nursing News. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Sotigalimab/Pembrolizumab Displays Promising Response Rate in Metastatic Melanoma

November 20, 2022

Article

Sotigalimab, a humanized IgG1 monoclonal antibody against human CD40, may hold value in the frontline treatment of patients with metastatic melanoma.

Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADT

May 16, 2022

Article

A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.

Niraparib Showcases Improved Health-Related QOL, Reduced Pain Burden in mCRPC

May 05, 2022

Article

Niraparib improved or maintained health-related quality of life, pain intensity, and pain interference in patients with advanced or metastatic castration-resistant prostate cancer.

Single Nucleotide Polymorphism Genotyping Could Predict Severe Radiation Dermatitis in Breast Cancer

May 05, 2022

Article

Single nucleotide polymorphism (SNP) genotyping could be used to predict radiation dermatitis in patients with breast cancer.

Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC

May 02, 2022

Article

The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.

Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Shows Efficacy, Tolerability in CLL

May 01, 2022

Article

The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.

Very Low-Dose RT Is Effective, Although Not Standard in Indolent Non-Hodgkin Lymphoma

April 29, 2022

Article

Very low dose radiation therapy was found to be an effective treatment approach in the palliative setting for patients with indolent non-Hodgkin lymphoma.

2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLC

April 15, 2022

Article

Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.

FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer

March 14, 2022

Article

Olaparib is now FDA approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer and who have already undergone chemotherapy before or after surgery.

Frontline Olaparib/Abiraterone Combo Extends Radiographic PFS in mCRPC

February 18, 2022

Article

First-line treatment with olaparib plus abiraterone resulted in a 34% risk reduction of radiographic disease progression or death in patients with metastatic castration-resistant prostate cancer.